Oppenheimer Assigned a Buy Rating to Endologix IncBy Jason Carr
According to TipRanks.com, Lichtman is a 1-star analyst with an average return of -1.7% and a 56.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Zimmer Biomet Holdings, and Integra Lifesciences.
Currently, the analyst consensus on Endologix Inc is Moderate Buy and the average price target is $10.33, representing a 32.9% upside.
In a report issued on November 16, BTIG also maintained a Buy rating on the stock with a $11 price target.
The company has a one year high of $14.50 and a one year low of $6.22. Currently, Endologix Inc has an average volume of 1.25M.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2016, Jose Lima, the VP-Quality of ELGX sold 4,710 shares for a total of $55,013.
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, VELA Proximal Endograft, Intuitrak Endovascular AAA System, and Nellix Endovascular Aneurysm Sealing System. The company was founded in March 1992 and is headquartered in Irvine, CA.